Miruvor
Sign up
The short answer

What studies of monoclonal antibodies (unspecified) found

21papers on monoclonal antibodies (unspecified)
4,079people in 3 studies testing monoclonal antibodies (unspecified) alone, and 9,371 patients in 3 health-record studies, counted apart
0randomised trials, the strongest kind of study

At a glance, by condition

Preventing long COVID: D Little or no difference

Based on the strongest evidence, compared with another group, not randomised (very low certainty): 7 of 11 findings are D.

11 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with monoclonal antibodies (unspecified) for preventing long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 21 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Monoclonal antibodies (unspecified) · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Preventing long COVID

Symptoms

Breathlessness5 studies · 13,208 people received monoclonal antibodies (unspecified) Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance; the studies disagree; controlled studies found mixed results.

Compared with another group, not randomised4 studies · 106,801 people with results

Studies disagree about breathlessness.

Studies disagree about whether monoclonal antibodies (unspecified) helps breathlessness. Mixed results · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
  • The studies disagree

Studies with no comparison group39 in the study · single 700 mg intravenous (IV) infusion · 700 mg, single infusion

Too little to say about breathlessness.

Too little to say: breathlessness got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (39 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 5 studies
  1. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    Shortness of Breath
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA. (2023)

    People in the study
    —
    Dose
    —
    Outcome
    Respiratory
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching The following variables were used to generate a propensity score: gender (male, female), geography (census region (Northeast, North Central, South, West)), locale (urban, suburban, rural), baseline Elixhauser Comorbidity Index
    Selection of participants
    Moderate. comparison group: propensity score matching From the set of 327 079 eligible patients who did not receive MAb treatment, we created a one-to-one matched comparison group that did not receive MAb therapy (any COVID-19 treatment other than MAb therapy was allowed) using propensity score matching.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 11 treatment-group individuals had no adequate match; final matched analytical sample 3798 treated patients There were 11 individuals in the treatment group for whom an adequate match (matching criteria described in the next section) could not be found.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Serious. a exploratory result
  3. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population. (2023)

    People in the study
    55,192 in the study · 53,239 started · 53,239 with outcome data
    Dose
    as per consistently defined clinical criteria
    Outcome
    persistent shortness of breath
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age; sex; race; ethnicity; Charlson Comorbidity Index (CCI); COVID-19 illness severity; state (Texas) area deprivation index (ADI); Models were adjusted for age (18–39, 40–64, 65+ years), sex, race, ethnicity, Charlson Comorbidity Index (CCI; 0–1, 2–4, 5+), and COVID-19 illness severity categorised as mild/ambulatory disease; Models were also adjusted for state (Texas) area deprivation index (ADI; 0–3, 4–6, 7+), a composite measure of socioeconomic disadvantage
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 1953 (3.5%) were excluded due to missing or unverifiable data 1953 (3.5%) were excluded due to missing or unverifiable data
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  4. Real World Evidence of Effectiveness of COVID-19 Vaccines and Anti SARS-CoV-2 Monoclonal Antibodies Against Post-Acute Sequelae of SARS-CoV-2 Infection (2022) preprint

    People in the study
    55,192 in the study · 53,239 started · 53,239 with outcome data
    Dose
    as per consistently defined clinical criteria
    Outcome
    persistent shortness of breath
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, race, ethnicity, area deprivation index, Charlson Comorbidity Index, COVID-19 illness severity adjusted for age (18 to 39, 40 to 64, 65+ years), sex, race, ethnicity, area deprivation index (ADI: 0 to 3, 4 to 6, 7+),6 Charlson Comorbidity Index (CCI: 0 to 1, 2 to 4, 5+),7 and COVID-19 illness severity
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 1,953 (3.5%) were excluded due to missing or unverifiable data 1,953 (3.5%) were excluded due to missing or unverifiable data
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  5. Early Treatment with Bamlanivimab Alone does not Prevent COVID-19 Hospitalization and Its Post-Acute Sequelae. A Real Experience in Umbria, Italy. (2021)

    People in the study
    39 in the study
    Dose
    700 mg, single infusion
    Outcome
    dyspnea
    Effect
    worse (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Anxiety3 studies · 9,371 people received monoclonal antibodies (unspecified) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance.

Compared with another group, not randomised3 studies · 106,801 people with results

Anxiety improved more than in the comparison group.

The evidence is very uncertain about the effect of monoclonal antibodies (unspecified) on anxiety later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
See the 3 studies
  1. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    Generalized Anxiety Disorder-7
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population. (2023)

    People in the study
    55,192 in the study · 53,239 started · 53,239 with outcome data
    Dose
    as per consistently defined clinical criteria
    Outcome
    new onset of mood/anxiety disorders
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age; sex; race; ethnicity; Charlson Comorbidity Index (CCI); COVID-19 illness severity; state (Texas) area deprivation index (ADI); Models were adjusted for age (18–39, 40–64, 65+ years), sex, race, ethnicity, Charlson Comorbidity Index (CCI; 0–1, 2–4, 5+), and COVID-19 illness severity categorised as mild/ambulatory disease; Models were also adjusted for state (Texas) area deprivation index (ADI; 0–3, 4–6, 7+), a composite measure of socioeconomic disadvantage
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 1953 (3.5%) were excluded due to missing or unverifiable data 1953 (3.5%) were excluded due to missing or unverifiable data
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Real World Evidence of Effectiveness of COVID-19 Vaccines and Anti SARS-CoV-2 Monoclonal Antibodies Against Post-Acute Sequelae of SARS-CoV-2 Infection (2022) preprint

    People in the study
    55,192 in the study · 53,239 started · 53,239 with outcome data
    Dose
    as per consistently defined clinical criteria
    Outcome
    new onset of mood/anxiety disorders
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, race, ethnicity, area deprivation index, Charlson Comorbidity Index, COVID-19 illness severity adjusted for age (18 to 39, 40 to 64, 65+ years), sex, race, ethnicity, area deprivation index (ADI: 0 to 3, 4 to 6, 7+),6 Charlson Comorbidity Index (CCI: 0 to 1, 2 to 4, 5+),7 and COVID-19 illness severity
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 1,953 (3.5%) were excluded due to missing or unverifiable data 1,953 (3.5%) were excluded due to missing or unverifiable data
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Smell and taste loss1 study · 101 people received monoclonal antibodies (unspecified) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised102 in the study · 323 with outcome data · baseline through 6-month follow-up

Smell and taste loss improved more than in the comparison group.

The evidence is very uncertain about the effect of monoclonal antibodies (unspecified) on smell and taste loss later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    smell and other neurological symptoms at 1 month
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Fatigue3 studies · 3,938 people received monoclonal antibodies (unspecified) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised2 studies · 323 people with results

No clear difference in fatigue.

The evidence is very uncertain about the effect of monoclonal antibodies (unspecified) on fatigue later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance

Studies with no comparison group39 in the study · single 700 mg intravenous (IV) infusion · 700 mg, single infusion

Too little to say about fatigue.

Too little to say: fatigue got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (39 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 3 studies
  1. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    FACIT-F Fatigue Scale Functional Assessment of Chronic Illness Therapy- Fatigue
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA. (2023)

    People in the study
    —
    Dose
    —
    Outcome
    Fatigue
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching The following variables were used to generate a propensity score: gender (male, female), geography (census region (Northeast, North Central, South, West)), locale (urban, suburban, rural), baseline Elixhauser Comorbidity Index
    Selection of participants
    Moderate. comparison group: propensity score matching From the set of 327 079 eligible patients who did not receive MAb treatment, we created a one-to-one matched comparison group that did not receive MAb therapy (any COVID-19 treatment other than MAb therapy was allowed) using propensity score matching.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 11 treatment-group individuals had no adequate match; final matched analytical sample 3798 treated patients There were 11 individuals in the treatment group for whom an adequate match (matching criteria described in the next section) could not be found.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Serious. a exploratory result
  3. Early Treatment with Bamlanivimab Alone does not Prevent COVID-19 Hospitalization and Its Post-Acute Sequelae. A Real Experience in Umbria, Italy. (2021)

    People in the study
    39 in the study
    Dose
    700 mg, single infusion
    Outcome
    asthenia
    Effect
    worse (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)2 studies · 3,899 people received monoclonal antibodies (unspecified) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised2 studies · 323 people with results

No clear difference in cognition (brain fog).

The evidence is very uncertain about the effect of monoclonal antibodies (unspecified) on cognition (brain fog) later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 2 studies
  1. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    Post SARS-CoV-2 Cognitive Questions
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA. (2023)

    People in the study
    —
    Dose
    —
    Outcome
    Amnesia
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching The following variables were used to generate a propensity score: gender (male, female), geography (census region (Northeast, North Central, South, West)), locale (urban, suburban, rural), baseline Elixhauser Comorbidity Index
    Selection of participants
    Moderate. comparison group: propensity score matching From the set of 327 079 eligible patients who did not receive MAb treatment, we created a one-to-one matched comparison group that did not receive MAb therapy (any COVID-19 treatment other than MAb therapy was allowed) using propensity score matching.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 11 treatment-group individuals had no adequate match; final matched analytical sample 3798 treated patients There were 11 individuals in the treatment group for whom an adequate match (matching criteria described in the next section) could not be found.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Serious. a exploratory result
Low mood or anxiety2 studies · 3,899 people received monoclonal antibodies (unspecified) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised2 studies · 323 people with results

No clear difference in low mood or anxiety.

The evidence is very uncertain about the effect of monoclonal antibodies (unspecified) on low mood or anxiety later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 2 studies
  1. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    FACIT-F Emotional Well-being Functional Assessment of Chronic Illness Therapy- Fatigue
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA. (2023)

    People in the study
    —
    Dose
    —
    Outcome
    Mental health
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching The following variables were used to generate a propensity score: gender (male, female), geography (census region (Northeast, North Central, South, West)), locale (urban, suburban, rural), baseline Elixhauser Comorbidity Index
    Selection of participants
    Moderate. comparison group: propensity score matching From the set of 327 079 eligible patients who did not receive MAb treatment, we created a one-to-one matched comparison group that did not receive MAb therapy (any COVID-19 treatment other than MAb therapy was allowed) using propensity score matching.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 11 treatment-group individuals had no adequate match; final matched analytical sample 3798 treated patients There were 11 individuals in the treatment group for whom an adequate match (matching criteria described in the next section) could not be found.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Serious. a exploratory result
Sleep2 studies · 140 people received monoclonal antibodies (unspecified) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance; effect size 0.00 (very small).

Compared with another group, not randomised102 in the study · 323 with outcome data · baseline through 6-month follow-up

No clear difference in sleep.

The evidence is very uncertain about the effect of monoclonal antibodies (unspecified) on sleep later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • Effect size 0.00 (very small)

How big was the difference?

0, very small. The effect size compares monoclonal antibodies (unspecified) with non-mab.

Studies with no comparison group39 in the study · single 700 mg intravenous (IV) infusion · 700 mg, single infusion

Too little to say about sleep.

Too little to say: sleep got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (39 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 2 studies
  1. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    Difficulty Sleeping
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Early Treatment with Bamlanivimab Alone does not Prevent COVID-19 Hospitalization and Its Post-Acute Sequelae. A Real Experience in Umbria, Italy. (2021)

    People in the study
    39 in the study
    Dose
    700 mg, single infusion
    Outcome
    onset of a new symptom: insomnia
    Effect
    worse (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression1 study · 101 people received monoclonal antibodies (unspecified) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised102 in the study · 323 with outcome data · baseline through 6-month follow-up

No clear difference in depression.

The evidence is very uncertain about the effect of monoclonal antibodies (unspecified) on depression later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    Patient Health Questionnaire-9
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Daily life and health overall

Overall symptoms5 studies · 13,411 people received monoclonal antibodies (unspecified) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree; effect size 0.48 (small).

Compared with another group, not randomised5 studies · 107,450 people with results

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of monoclonal antibodies (unspecified) on overall symptoms later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
  • Effect size 0.48 (small)

How big was the difference?

0.48, small. The effect size compares monoclonal antibodies (unspecified) with antiviral drugs.

See the 5 studies
  1. The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study. (2023)

    People in the study
    649 in the study
    Dose
    —
    Outcome
    death or hospitalisation for COVID-19 at 1/3 months
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. adjusted for: sex, age, vaccination status, treatment, treatment group, number of comorbidities The included covariates were sex, age (in categories < 65, 65–79, 80 + for the primary outcome and in continuous for the secondary outcomes), vaccination status
    Selection of participants
    Moderate. comparison group: eligible patients who refused treatment controls (eligible patients who refused treatment)
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Long COVID data available for 323 (49.8%); handling not reported Data on long COVID at 3 months were available for 323 (49.8%) patients.
    Measurement of outcomes
    Low. an objective measure
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  2. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    Number of Symptoms
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA. (2023)

    People in the study
    —
    Dose
    —
    Outcome
    one or more clinical sequelae in the postacute phase
    Effect
    worse
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching The following variables were used to generate a propensity score: gender (male, female), geography (census region (Northeast, North Central, South, West)), locale (urban, suburban, rural), baseline Elixhauser Comorbidity Index
    Selection of participants
    Moderate. comparison group: propensity score matching From the set of 327 079 eligible patients who did not receive MAb treatment, we created a one-to-one matched comparison group that did not receive MAb therapy (any COVID-19 treatment other than MAb therapy was allowed) using propensity score matching.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 11 treatment-group individuals had no adequate match; final matched analytical sample 3798 treated patients There were 11 individuals in the treatment group for whom an adequate match (matching criteria described in the next section) could not be found.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Serious. a exploratory result
  4. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population. (2023)

    People in the study
    55,192 in the study · 53,239 started · 53,239 with outcome data
    Dose
    as per consistently defined clinical criteria
    Outcome
    PASC
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age; sex; race; ethnicity; Charlson Comorbidity Index (CCI); COVID-19 illness severity; state (Texas) area deprivation index (ADI); Models were adjusted for age (18–39, 40–64, 65+ years), sex, race, ethnicity, Charlson Comorbidity Index (CCI; 0–1, 2–4, 5+), and COVID-19 illness severity categorised as mild/ambulatory disease; Models were also adjusted for state (Texas) area deprivation index (ADI; 0–3, 4–6, 7+), a composite measure of socioeconomic disadvantage
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 1953 (3.5%) were excluded due to missing or unverifiable data 1953 (3.5%) were excluded due to missing or unverifiable data
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  5. Real World Evidence of Effectiveness of COVID-19 Vaccines and Anti SARS-CoV-2 Monoclonal Antibodies Against Post-Acute Sequelae of SARS-CoV-2 Infection (2022) preprint

    People in the study
    55,192 in the study · 53,239 started · 53,239 with outcome data
    Dose
    as per consistently defined clinical criteria
    Outcome
    PASC
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, race, ethnicity, area deprivation index, Charlson Comorbidity Index, COVID-19 illness severity adjusted for age (18 to 39, 40 to 64, 65+ years), sex, race, ethnicity, area deprivation index (ADI: 0 to 3, 4 to 6, 7+),6 Charlson Comorbidity Index (CCI: 0 to 1, 2 to 4, 5+),7 and COVID-19 illness severity
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 1,953 (3.5%) were excluded due to missing or unverifiable data 1,953 (3.5%) were excluded due to missing or unverifiable data
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
Daily functioning1 study · 101 people received monoclonal antibodies (unspecified) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised102 in the study · 323 with outcome data · baseline through 6-month follow-up

No clear difference in daily functioning.

The evidence is very uncertain about the effect of monoclonal antibodies (unspecified) on daily functioning later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    FACIT-F Functional Well-being Functional Assessment of Chronic Illness Therapy- Fatigue
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Quality of life1 study · 101 people received monoclonal antibodies (unspecified) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised102 in the study · 323 with outcome data · baseline through 6-month follow-up

No clear difference in quality of life.

The evidence is very uncertain about the effect of monoclonal antibodies (unspecified) on quality of life later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection. (2023)

    People in the study
    102 in the study · 323 with outcome data
    Dose
    —
    Outcome
    FACIT-F Physical Well-being Functional Assessment of Chronic Illness Therapy- Fatigue
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Non-randomised: patients in the same health system who tested positive for SARS-CoV-2 and did not receive mAb treatment. received standard of care for acute SARS-CoV-2
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete records excluded from analysis; cases lost to follow-up analysed cross-sectionally for timepoints collected and excluded from time point comparisons. Cases lost to follow-up longitudinally were analyzed cross-sectionally for timepoints collected and excluded from time point comparisons.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Side effects

Side effects studies reported2 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Trouble sleeping2 studies
Worse symptoms or a flare1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    700 mg at the start

  2. 2Top dose

    Most often 700 mg (2 of 2 studies)

Doses across 2 studies

700 to 700 mg.

Each study’s dose, as printed

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

Meta-analysisPublished 2024Searched to up to January 29, 2024

The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis. (2024)

“The pooled effect size shows that mAbs treatment during acute COVID-19 has no effect on long COVID incidence (OR, 0.94; 95% CI, 0.56e1.56; p 0.8012; I2, 72%)”
“No evidence of a relationship between mAbs treatment and long COVID incidence can be derived from the results of this study.”

All papers

  1. Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.2024 · placebo trial · 847 randomised · 780 started · 780 analysed
    Summary

    This randomized, double-blind, placebo-controlled phase 2/3 trial asked whether early amubarvimab/romlusevimab reduces late COVID-19 outcomes, including Long COVID. It enrolled 847 and analysed 780 outpatient adults ≥18 years at high risk of severe COVID-19; 390 received amubarvimab 1000 mg then romlusevimab 1000 mg by IV on day 0 and 390 received saline placebo. Follow-up was at week 36. The primary composite was Long COVID at week 36 or hospitalization/death by week 36: 66 (17%) versus 92 (24%), wRR 0.70 (95% CI 0.53–0.93; p=0.01). Hospitalizations/deaths were 17 (4%) versus 52 (13%), RR 0.33 (95% CI 0.19–0.56; p<0.001). Among 652 with diary responses, Long COVID was reported by 53 (16%) versus 44 (14%). Death or Long COVID was 54 (14%) versus 55 (14%), wRR 0.90 (95% CI 0.64–1.27; p=0.55). Not returning to usual health was 16% versus 22%; failure to return to health or death wRR 0.65 (95% CI 0.48–0.89; p=0.006). At least one of 27 symptoms was reported by 41% versus 39%. The paper reports no significant differences for worst symptom score (p=0.76), number of symptoms (p=0.85), total symptom score (p=0.83), symptom categories (p≥0.21), individual symptoms (p≥0.14), or HRQOL domains. Hospitalizations before day 28 were 9 versus 43; after day 28, 7 versus 9. Deaths were 12: 11 in placebo within first 28 days and one in amubarvimab/romlusevimab after day 28. The paper does not report side effects or withdrawals for harms.

  2. Administration of antivirals, IL-6 inhibitors, monoclonal neutralizing antibodies and systemic corticosteroids in acute SARS-CoV-2 infection do not reduce the subsequent burden of Long-COVID symptoms.2025 · compared with another group · 1,910 in the study · 1,534 with outcome data
    Summary

    This observational cohort study asked whether drugs given during acute SARS-CoV-2 infection were associated with later Long-COVID symptoms. Data were entered for 1910 patients; 1534 adults were analysed after exclusions. Patients came from Long-COVID centres. Treatment groups were defined by whether patients received antivirals (318), oral or IV steroids (810), IL-6 inhibitors (144), or neutralizing monoclonal antibodies (60) during acute infection; treatment duration is not reported. Symptoms were assessed a mean 338 days after acute infection. The paper reports that some protective associations seen in univariate analyses were not confirmed in multivariable analyses. In adjusted analyses, IL-6 inhibitors were associated with an increased risk of cough (AOR 3.41, 95% CI 1.84-6.41, p<0.001). Steroids were associated with increased risks of dyspnea (AOR 1.56, 95% CI 1.12-2.17, p=0.008), joint pain or swelling (AOR 1.76, 95% CI 1.16-2.67, p=0.008), and muscle pain (AOR 2.02, 95% CI 1.35-3.03, p<0.001). No withdrawal counts were reported. The authors note limitations including retrospective symptom assessment in most cases and possible selection bias.

  3. Association of COVID vaccinations and treatments with long COVID beyond 6 months: a case-control study on the adult population in a large integrated healthcare system in the United States from 2020 to 2023.2025 · compared with another group · 840 with outcome data
    Summary

    This case-control study used electronic medical records from Kaiser Permanente Southern California to examine whether COVID vaccination or acute COVID treatments were associated with Long COVID at least 6 months after infection. Adults with Long COVID diagnosed by ICD-10 code were matched to controls without Long COVID by age, sex, race/ethnicity, body mass index, and date of acute COVID infection. The January 2022 to June 2023 analysis included 840 cases and 4200 controls; the October 2020 to June 2023 analysis included 2632 cases and 13,160 controls. Patients with a history of ME/CFS or fibromyalgia fulfilling ME/CFS criteria were excluded. Compared with no vaccination, one dose was associated with lower odds of Long COVID (OR 0.77; 95 % CI 0.63–0.96), two doses (OR 0.73; 95 % CI 0.59–0.92), three doses (OR 0.66; 95 % CI 0.44–1.00), and four doses (OR 0.29; 95 % CI 0.06–1.49). Nirmatrelvir/ritonavir was associated with lower odds (OR 0.05; 95 % CI 0.04–0.07), as was remdesivir (OR 0.31; 95 % CI 0.19–0.49). No interaction was found between nirmatrelvir/ritonavir and one, two, or three vaccinations (p = 0.38, p = 0.24, p = 0.08); an interaction was found with four doses (p = 0.002). No interaction was found between remdesivir and one to four vaccinations (p = 0.74, p = 0.92, p = 0.96, p = 0.98). No harms or withdrawals were reported. The authors state the case-control design cannot establish causality and note possible misclassification of the index infection and limited power.

  4. Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data.2025 · compared with another group · 9,504 with outcome data
    Summary

    This retrospective cohort study used US National COVID Cohort Collaborative (N3C) data to assess whether early sotrovimab treatment, compared with no treatment, was associated with post-acute sequelae of COVID-19 (PASC, long COVID) in high-risk patients with COVID-19. The main analysis included 9,504 sotrovimab-treated and 619,668 untreated patients. The observation period ran from day 30 following diagnosis until the earliest of day 365 following diagnosis, loss to follow-up, end of data availability, death, COVID-19 re-infection, or initiation of another mAb, antiviral, or pre-exposure prophylaxis. PASC was defined as at least one PASC symptom at least 30 days after the first COVID-19 diagnosis. PASC occurred in 6,217 (65.4%) treated patients and 324,289 (52.3%) untreated patients. The unweighted HR was 1.42 (95% CI 1.38–1.46), p < 0.001. The doubly robust ATT-weighted HR was 0.92 (0.89–0.96), p < 0.001. With administrative censoring, the HR was 0.95 (0.92–0.98), p < 0.001. With a more stringent PASC definition, the HR was 0.89 (0.74–1.07), p = 0.21, not statistically significant. The adjusted HR from multivariable Cox regression was 0.96 (0.94–0.99), p < 0.001. Subgroup HRs were 0.92 (0.89–0.95) for adults and 0.94 (0.91–0.98) for the highest-risk subgroup; for hospitalization and/or ICU admission during the acute phase, the HR was 1.14 (0.91–1.44), p = 0.25, with no significant difference between cohorts. Harms and withdrawals for harms were not reported. The authors state limitations including observational EHR data, residual or unmeasured confounding, channeling bias, immortal time bias, and heterogeneity in PASC definitions.

  5. Risk factors and early preventive measures for long COVID in non-hospitalized patients: analysis of a large cohort in the United Arab Emirates.2024 · compared with another group · 28,375 in the study
    Summary

    This cohort study asked which patient-specific factors were associated with long COVID and whether pre-COVID vaccination or treatments received during acute COVID-19 were associated with long COVID risk. It included 28,375 non-hospitalized adult patients diagnosed with mild to moderate COVID-19 in Dubai between January 1, 2021, and September 31, 2022, who were followed up for 90 days. The presence of long COVID symptoms was documented by physicians during patient visits to the family medicine department. The abstract reports that pre-COVID vaccination was associated with a reduced risk of long COVID in all patient subgroups. It also reports that treatment with favipiravir or sotrovimab during the acute phase of COVID-19 was linked to a decreased risk of long COVID, although the abstract notes a limit for favipiravir in the high-risk group. Doses and treatment duration are not reported. The abstract reports no side effects, harms, or withdrawals due to harms for any arm. The authors conclude that the study identifies risk factors for long COVID among non-hospitalized patients and emphasizes the potential benefits of pre-COVID vaccination and timely treatment. The abstract does not state limitations.

  6. Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19.2024 · compared with another group · 716 in the study · 571 with outcome data
    Summary

    This retrospective cohort study at the Ralph H. Johnson Veterans Affairs hospital screened 716 veterans with mild-moderate COVID-19 for outpatient monoclonal antibody eligibility between December 1, 2020, and October 31, 2021. Of these, 571 were included in the final analysis: 296 in the mAb group and 275 in the control group. The mAb group received a single infusion of bamlanivimab, bamlanivimab-etesevimab, or casirivimab-imdevimab; the control group did not receive a mAb infusion. Outcomes were assessed within 30 days, with post-COVID-19 conditions assessed 31 to 90 days after infusion or screening. The primary outcome of all return ED visits and/or hospitalizations was 25.7% in the mAb group vs 25.1% in the control group (P = 0.87). COVID-19-related return ED visits and/or hospitalizations were 13.9% vs 16% (P = 0.4). All return ED visits were 18.6% vs 11.3% (P = 0.02), return ED visits for COVID-19 were 9.5% vs 7.3% (P = 0.35), all hospitalizations were 7.1% vs 13.5% (P = 0.01), and hospitalizations for COVID-19 were 4.4% vs 9.1% (P = 0.02). Death within 30 days occurred in 2 vs 3 patients (P = 0.59). Post-COVID-19 conditions occurred in 12.1% vs 3.3% (P < 0.01). No patients experienced adverse reactions in the immediate 1-hour observation period; four nonsevere adverse events occurred after mAb therapy, and four patients experienced an adverse event after the observation period, two of which resulted in hospitalization. Withdrawals due to harms were not reported.

  7. Association between monoclonal antibody therapy, vaccination, and longer-term symptom resolution after acute COVID-19.2024 · compared with another group · 1,854 in the study · 1,612 with outcome data
    Summary

    This longitudinal prospective cohort study surveyed adults with a positive SARS-CoV-2 test from a Colorado health system to examine whether monoclonal antibody (mAb) therapy or COVID-19 vaccination was associated with symptom recovery after acute COVID-19. Of 1854 participants who completed at least one survey, 1612 were analysed: 539 received mAb therapy and 1073 were untreated; 486 had received at least 2 vaccinations. The median time of the first survey was 78 (IQR 59 to 99) days after acute infection. The primary outcome was time to symptom resolution; 28-day hospitalization was secondary. Overall time to symptom resolution was not associated with mAb treatment (aHR 0.87, 95% CI 0.73 to 1.03, p=0.09). The neurologic symptom group had a significant difference (aHR 0.84, 95% CI 0.72 to 0.98, p=0.03). Time to resolution was shorter with at least 2 vaccinations versus unvaccinated (aHR 1.56, 95% CI 1.31 to 1.88, p<0.01) and with one vaccination versus unvaccinated (aHR 1.43, 95% CI 1.14 to 1.79, p<0.01). 28-day hospitalization was lower with mAb therapy (5% versus 12%; adjusted OR 0.31, 95% CI 0.19 to 0.50, p<0.01) and with vaccination (2+ vaccines 5%, 1 vaccine 7%, no vaccines 13%; adjusted OR 0.33, 95% CI 0.20 to 0.55, p=0.01 for 2+ vaccines and adjusted OR 0.42, 95% CI 0.21 to 0.79, p<0.01 for 1 vaccine). Harms were not reported.

  8. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA.2023 · compared with another group
    Summary

    This retrospective cohort study used USA administrative claims from Medicare Advantage and commercially insured health plan enrollees to examine whether monoclonal antibody (MAb) therapy given for COVID-19 changed 30-day and 90-day outcomes, including postacute sequelae. The MAb group was compared with a propensity-score matched standard-of-care group. A sample of 3809 individuals was identified for the treatment arm; after 11 treatment-group individuals could not be adequately matched, 3798 MAb-treated patients were analysed, alongside 3798 matched comparison patients who did not receive MAb therapy. MAb components listed were bamlanivimab, bamlanivimab-etesevimab and REGN-COV2, given intravenously. In the first 30 days, 156 MAb-treated individuals (4.1%) were hospitalised versus 213 (5.6%) in the comparison group (OR=0.72, 95% CI 0.58 to 0.89); ICU admission was 34 (0.9%) versus 57 (1.5%) (OR=0.59, 95% CI 0.39 to 0.91). In the postacute period (31–90 days), hospitalisation was 70 (1.8%) versus 59 (1.6%) (OR=1.19, 95% CI 0.84 to 1.69) and ICU admittance 21 (0.6%) versus 26 (0.7%) (OR=0.81, 95% CI 0.45 to 1.44). No differences were seen in clinical sequelae during the first 30 days (p=0.50), while a higher proportion treated with MAb sought care for one or more sequelae in the postacute phase (p=0.018). Harms were not reported.

  9. The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study.2023 · compared with another group · 649 in the study
    Summary

    This retrospective observational study asked whether early COVID-19 therapies affected death, hospitalization and persisting symptoms. It included 649 outpatients with mild-to-moderate COVID-19 evaluated from April 2021 to March 2022 in Brescia, Italy. Of these, 242 were treated with monoclonal antibodies, 197 with antiviral drugs and 210 were not treated (controls who refused treatment). Treatment duration was not reported. Data were collected at baseline and after 1 and 3 months; long COVID was assessed at 3 months. Overall, 29 patients (4.5%) died or were hospitalized at 1 or 3 months. Death or hospitalization was positively associated with older ages (OR 3.05, 95% CI 1.16–8.06 for patients aged 80 or more years compared to those aged less than 65), and no statistically significant associations emerged for treatment group. Long COVID data were available for 323 (49.8%) patients; prevalence of at least one symptom at 3 months was 29.1%. Antiviral drugs were associated with lower odds of any symptoms (OR 0.43, 95% CI 0.21–0.87), and monoclonal antibodies with lower odds of neurobehavioral symptoms (OR 0.48, 95% CI 0.25–0.92). For monoclonal antibodies, the OR for any symptoms was 0.78 (95% CI 0.44–1.36); for antiviral drugs, the OR for neurobehavioral symptoms was 0.51 (95% CI 0.24–1.10). Harms, side effects and withdrawals were not reported. The authors state limitations including retrospective design, small subgroup sample size, self-reported binary symptoms and no information on symptomatic treatments.

  10. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population.2023 · compared with another group · 55,192 in the study · 53,239 started · 53,239 with outcome data
    Summary

    This retrospective cohort study used the Houston Methodist COVID-19 Surveillance and Outcomes Registry, an electronic medical record-based registry from an eight-hospital tertiary hospital system in the Houston metropolitan area, to evaluate COVID-19 vaccination and anti-SARS-CoV-2 monoclonal antibodies (mAbs) against postacute sequelae of SARS-CoV-2 infection (PASC). The primary analysis identified 55,192 adult PCR-positive patients; 1,953 (3.5%) were excluded for missing or unverifiable data, leaving 53,239 analyzed. Among them, 3,781 (7.1%) were breakthrough COVID-19 cases and 4,635 (8.7%) were mAb-treated patients. PASC was defined as constitutional or systemic symptoms beyond the 28-day postinfection period; 5,929 (11.1%, 95% CI 10.9% to 11.4%) met PASC criteria. In fully adjusted models, vaccinated breakthrough cases versus unvaccinated patients had a lower likelihood of PASC, aOR 0.58 (95% CI 0.52 to 0.66), and mAb-treated versus untreated patients had aOR 0.77 (95% CI 0.69 to 0.86). A replication dataset included 631,683 patients; 70,648 (11.2%, 95% CI 11.1 to 11.3) had PASC, with aOR 0.25 (95% CI 0.21 to 0.30) for vaccine and 0.62 (95% CI 0.59 to 0.66) for mAb treatment. Vaccination was reported to confer greater protection across PASC symptoms than mAb treatment. Harms and treatment withdrawals were not reported.

  11. Real World Evidence of Effectiveness of COVID-19 Vaccines and Anti SARS-CoV-2 Monoclonal Antibodies Against Post-Acute Sequelae of SARS-CoV-2 Infection2022 · compared with another group · 55,192 in the study · 53,239 started · 53,239 with outcome data · preprint
    Summary

    This retrospective cohort study used the Houston Methodist COVID-19 Surveillance and Outcomes Registry (CURATOR) to examine COVID-19 vaccination and anti-SARS-CoV-2 monoclonal antibody (mAb) treatment against Post-Acute Sequelae of SARS-CoV-2 infection (PASC) in adults who survived beyond 28 days of index infection. The authors identified 55,192 adult PCR-positive patients; 1,953 (3.5%) were excluded for missing or unverifiable data, leaving 53,239 subjects. The cohort included 3,781 (7.1%) breakthrough COVID-19 cases and 4,635 (8.7%) mAb-treated patients. PASC was defined as new constitutional or systemic symptoms/conditions beyond the 28-day post-infection period, excluding pre-COVID symptoms or symptoms resolving within four weeks. In fully adjusted models, vaccinated breakthrough cases versus unvaccinated cases had a lower likelihood of PASC, aOR 0.58 (CI 0.52 - 0.66), and mAb-treated versus untreated patients had aOR 0.77 (CI 0.69 - 0.86). Overall, 5,929, 11.1% (CI 10.9 - 11.4), met PASC criteria. Vaccination was associated with decreased odds of all constitutional and systemic symptoms except changes in taste and smell; mAb was associated with decreased likelihood of persistent shortness of breath and new onset mood/anxiety disorders. In a replication dataset of 631,683 patients, 70,648, 11.2% (CI 11.1 - 11.3), had PASC; aORs were 0.25 (0.21 - 0.30) for vaccine and 0.62 (0.59 - 0.66) for mAb. Harms and withdrawals were not reported.

  12. Long COVID After Bamlanivimab Treatment.2023 · no comparison group · 1,162 started · 506 with outcome data
    Summary

    Researchers studied 506 people with mild-to-moderate COVID-19 who received bamlanivimab 700 mg as a one-time intravenous infusion in an outpatient trial and completed long-term symptom diaries at week 24. The analysis included 506 of 1162 people who received bamlanivimab; there was no placebo comparison group. At 24 weeks, 18% (91/506) reported long COVID, defined as COVID-19 symptoms of at least mild severity in the preceding 4 weeks, and 15% (76/506) reported not returning to usual pre-COVID health. Among the 91 with long COVID, common symptoms included fatigue (55%), smell disorder (40%), difficulty concentrating/thinking (36%), breathing difficulties (31%), musculoskeletal pain (27%), and weakness (22%). Prevalence was similar for treatment within 5 days (18% [51/276]) and >5 days (17% [40/230]) from symptom onset. No harms or side effects were reported in the text. The authors state that all participants received bamlanivimab and, without a placebo group, they cannot formally conclude that the rates of long COVID were impacted by early antiviral therapy; they also note the study was performed before widespread vaccination and may not generalize to current variants.

  13. 536. Development of post acute sequelae of SARS-Cov-2 infection (long Covid) in outpatient receiving monoclonal antibodies2023 · no comparison group · 1,100 in the study · 615 with outcome data
    Summary

    This study examined long COVID development in high-risk symptomatic COVID patients who received monoclonal antibody (mAb) treatment at an outpatient infusion center from April 2021-22. The authors called 1100 patients and obtained 615 responses. No comparison group was reported. A follow-up closed-ended survey asked whether patients experienced long COVID symptoms including fatigue, exertion intolerance, persistent cough or chest pain, dyspnea, brain fog, headaches, issues sleeping, myalgia, or loss of smell/taste. Of the 615 responses, 355 (57.7%) fully recovered and 260 (42.3%) reported experiencing long COVID. Among the 260 patients who reported long COVID, 12 (4.6%) were hospitalized. Also, 129 long COVID patients (50%) reported having 3 or more symptoms; the paper lists fatigue, brain fog and loss of smell/taste as the most prevalent. For harms, the paper reports the hospitalization count among patients with long COVID; it did not report withdrawals for harms. The authors conclude that long COVID was documented in almost half of high-risk symptomatic patients, suggesting a higher incidence compared to the literature despite a low hospitalization rate. They state that these results need to be validated in larger cohorts.

  14. Early Treatment with Bamlanivimab Alone does not Prevent COVID-19 Hospitalization and Its Post-Acute Sequelae. A Real Experience in Umbria, Italy.2021 · no comparison group · 39 in the study
    Summary

    This retrospective observational study in Umbria, Italy, asked whether early bamlanivimab monotherapy in recently infected patients with mild/moderate COVID-19 at high risk according to AIFA criteria affected hospitalization and later symptoms. A total of 39 patients received a single 700 mg intravenous infusion of bamlanivimab alone; follow-up was around thirty days after the infusion, with a telephone interview. There was no control group; the paper also compares patients treated early (within 3 days) with later treatment. No adverse events to treatment were observed, and no adverse events were documented in the following days. Eight patients were hospitalized: 4 for COVID-19 pneumonia and 4 for worsening underlying diseases. The hospitalization rate for any reason was 20%; the text reports 15% for COVID-19 related pathologies in the abstract and 10% for COVID-19 pneumoniae in the results. Between early and later treatment, the paper reports no differences in COVID-19 pneumonia hospitalization (3/15 vs. 2/24 p=0.289) or nasopharyngeal swab negativization (mean 16.58±4.10 vs. 16.70±4.63 days p=0.942). Thirty days after infusion, patients reported asthenia (77 vs. 51%), dyspnea (38.5 vs. 23%), tachypnea (44 vs. 33.3%), and in 41% onset of insomnia. The authors state limitations were the small number of subjects and absence of a control group.

  15. Long COVID: A Systematic Review of Preventive Strategies.2025 · systematic review
    Summary

    This systematic review asked whether treatments can prevent long COVID, defined as symptoms lasting three or more months after SARS-CoV-2 infection. The authors searched PubMed/MEDLINE for articles published between December 2019 and September 2024 and included 28 studies: fifteen on COVID-19 vaccination, seven on antivirals, and six on other treatments. Findings are reported study by study rather than pooled. For vaccination, ten out of fifteen studies demonstrated a protective effect against long COVID; Ayoubkhani et al. reported odds decreased by 12.8% after a first dose and by an additional 8.8% after a second dose compared with unvaccinated individuals, while Antonelli et al. found a booster did not reduce risk when long COVID was defined as symptoms lasting 12 weeks or longer. For antivirals, a randomized trial of remdesivir found no significant differences between treated and untreated groups, whereas Boglione et al. reported a 36% reduction in odds with remdesivir and Wang et al. reported nirmatrelvir/ritonavir reduced odds by 65%. Convalescent plasma showed no statistically significant reduction; metformin showed a 42% reduction in long COVID incidence; multiple micronutrient supplements for 2 weeks showed no differences. Luo et al. reported vaccination after infection increased risk of reporting long COVID symptoms, which may be due to side effects. No stopping data were recorded. The authors state that COVID-19 vaccines likely reduce the risk of developing long COVID, while evidence for antivirals and other drugs is still in its infancy.

  16. Preventive interventions for post Covid-19 condition: systematic review update2024 · systematic review · preprint
    Summary

    This systematic review update searched on February 9, 2024 and included 24 studies (5 randomized and 19 non-randomized), all among adults. It examined interventions given during acute or post-acute COVID-19 to prevent post COVID-19 condition (PCC). For convalescent plasma in outpatients (1 trial; N=882), the RR (95% CI) was 0.93 (0.77-1.12), with moderate certainty. For probiotics in outpatients (1 trial; N=69), RR was 0.32 (0.13-0.78), low certainty. For metformin in outpatients (1 trial; N=450), RR was 0.50 (0.25-0.99), low certainty. For ivermectin in outpatients (1 trial; N=374), RR was 0.93 (0.50-1.71), low certainty. Therapeutic-dose heparin versus prophylactic-dose heparin in inpatients (1 trial; N=571) had RR 1.11 (0.94-1.30) for PCC, low certainty; for cognitive impairment RR was 0.49 (0.22 to 1.07), low certainty; and for HRQoL the MD was 0.12 (-3.22 to 3.46) [range 0-100], moderate certainty. In one trial, metformin (n=569) had no serious adverse events per group; fluvoxamine (n=319), ivermectin (n=406), metformin and fluvoxamine (n=336), and metformin and ivermectin (n=401) had no events in any comparison.

  17. CROI 2023: Acute and Post-Acute COVID-19.2023 · review
    Summary

    This invited review summarized studies presented at CROI 2023 on acute COVID-19 and long COVID; it did not conduct its own study or enrol participants. It covered randomized trials and observational analyses, including a peginterferon lambda trial with more than 1900 mostly vaccinated, high-risk, nonhospitalized participants, an inhaled interferon-β1A trial with approximately 220 participants, a nirmatrelvir/ritonavir analysis of approximately 8000 propensity-matched people in the US Veterans Affairs health system, and 40 children treated in Rome. Ensitrelvir, given within 72 hours of symptom onset versus placebo, was associated with shortened symptom and infectious viral shedding duration by approximately 1 day each; at 6 months there was a 25% reduction in any long COVID symptoms and 26% in neurologic symptoms. Metformin was associated with higher odds of undetectable viral RNA at days 5 and 10 (OR, 1.355; 95% CI, 1.054-1.742) and a 42% reduction in long COVID through month 10. Nirmatrelvir/ritonavir was associated with a 98% relative reduction in hospitalization within 14 days versus no therapy. Peginterferon lambda was associated with a 58% risk reduction of hospitalization or emergency department visit within 3 days. Molnupiravir was not associated with significant reduction in hospitalization or death within 30 days versus no therapy; inhaled interferon-β1A did not accelerate RNA clearance over 2 weeks; amubarvimab plus romlusevimab had no effect on long COVID symptoms or quality of life at 36 weeks. Among 40 children, 5 adverse events occurred. Worsening and discontinuation counts were not reported. The authors stated that more data are needed.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime